Globus Medical has developed a portfolio for orthopedic trauma care from Investing.com

AUDUBON, Pa. – Globus Medical, Inc. (NYSE: GMED), one of the key workers in the musculoskeletal system, has enabled the production of orthopedic trauma dispensing. More new systems and the first processing of products, the TENSOR™ suture button systems, have been 510(k) approved by the U.S. Food and Drug Administration (FDA).

These new products scrub ANTHEM™ II Distal Radius Volarplates, AUTOBAHN™ Trochantäre Nagel PRO instruments and CAPTIVATE™ SOLA head floss. These experiences ensure that patient involvement in innovation and research by surgeons and patients in orthopedic trauma care will continue.

John Mulcahy, Chief Commercial Officer and President of Orthopedics at Globus, received positive feedback from US-American surgeons who have started using new implants and instruments in their practices. Dr. Asif Ilyas of Thomas Jefferson University Hospital, one of the users of ANTHEM™ II maps, has determined the quality of the systems so that an individual surgical plan can receive an anatomical passport.

The TENSOR™ suture button system could be deployed, follow-up treatment will result in operations. A self-study has been carried out and an inserter with integrated tension grips. The system is compatible with ANTHEM™ Knöchel- and One-Third Tubular-Platten and can provide an overall release for knöcheleingriffe.

The ANTHEM™ Distal Radius Fraktur System provides a handle for hand lung movements with anatomically shaped plates and market leading polyaxial relief technology. The AUTOBAHN™ Trochanteric Nail System is intended for the treatment of femoral fractures with instruments that allow efficient surgical treatment.

Darüber is the CAPTIVATE™ SOLA copier for a compression system that requires a lot of effort for Frakturversorgung, Knochenreconstruction, Osteotomy and Arthrodesis-Verfahren. There is a huge schrauben over time and length, which in Edelstahl also occurs in Titanlegierung.

Globus Medical’s move into the market for orthopedic trauma disruptive care could go hand in hand with the integration of the PRECICE™ magnetic beriebenen beinverlängerungsnagel technology, which could support the spectrum of the patient bed, the address could be obtained.

The information in this article is based on a press conference by Globus Medical, Inc.

In other cases, Globus Medical has performed medical treatment with the new ADIRA™ XLIF™ Plattensystems, which allow better treatment of lateral surgical procedures. This company has started a continuation of loans in the quarter of 2024, of which the 630 million US dollars has been returned and a value of 116% has been marketed in the past. Die Anstieg die wie sich über über beitgrund von des Gerätsbeitung von NuVasive-zugeschrieben, een factor, der zum Anstieg des nicht-GAAP-Gewinns pro Aktie op 0.75 US-Dollar beitrug, was a Steigerung of 20% in the annual comparison.

We are proud to inform you that Globus Medical has received a warning in the form of a warning from the US Food and Drug Administration (FDA). Here are the ways people with the product description and medical device report get started with the ExcelsiusGPS® robotic system. In response to the investigation into the Declaration of Independence, a new response from the FDA is a fact.

I think the analysts at Jefferies and Canaccord Genuity have their Kaufempfehlungen for Globus Medical at Globus Medical, while Truist Securities and Morgan Stanley look after their valuable interests. Analysts predict an average of US$2.47 billion and US$2.49 million, but GAAP earnings for the Action are worth US$2.80 and US$2.90. The investigation into Globus Medical has come to an end.

InvestingPro Acknowledgment

Globus Medical’s recent product innovations and advancements in the market for orthopedic trauma-disrupting care are in line with their strong financial leadership and market position among consumers. Laut InvestingPro-Daten versügt Globus Medical with a market capitalization of 9.48 billion US dollars, was one of the best prices in the industry for a broader mirror of the musculoskeletal system.

The second term ends with a value of 103.89% in the last month of 2024 and four years of 115.93% in the second half of 2024. This robust period continues to develop the quality of life, in new product tentwicklungen and marktweiterungen that invest, with the young FDA zulassungen and productinführungen.

InvestingPro-Tipps have said that Globus Medical’s net gain in those years is still developing a new product with the TENSOR™ suture button system and that there are more and more products for orthopedic trauma care that can be performed in this way. Because the debtor’s indebtedness was resolved with moderate indebtedness and liquid Mittel debt, the indebtedness of the indebtedness was solid financing

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.